Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Given Average Recommendation of "Moderate Buy" by Analysts

Tandem Diabetes Care, Inc. (NASDAQ:TNDM - Get Free Report) has been assigned a consensus recommendation of "Moderate Buy" from the eighteen research firms that are covering the company, Marketbeat.com reports. Three research analysts have rated the stock with a hold rating and fifteen have issued a buy rating on the company. The average twelve-month price objective among brokerages that have covered the stock in the last year is $53.81.

Several research analysts have issued reports on the company. Robert W. Baird cut their price target on Tandem Diabetes Care from $39.00 to $37.00 and set a "neutral" rating on the stock in a report on Thursday, November 7th. Morgan Stanley raised shares of Tandem Diabetes Care from an "equal weight" rating to an "overweight" rating and set a $45.00 price target for the company in a research report on Monday, December 2nd. Sanford C. Bernstein began coverage on shares of Tandem Diabetes Care in a report on Wednesday, November 6th. They set an "outperform" rating and a $42.00 price objective on the stock. Citigroup reduced their price objective on shares of Tandem Diabetes Care from $57.00 to $50.00 and set a "buy" rating for the company in a report on Wednesday, December 11th. Finally, Canaccord Genuity Group lowered their target price on shares of Tandem Diabetes Care from $57.00 to $56.00 and set a "buy" rating on the stock in a report on Thursday, November 7th.

Tandem Diabetes Care Stock Down 3.5 %

Shares of Tandem Diabetes Care stock traded down $1.12 during trading on Thursday, reaching $31.00. 906,169 shares of the company traded hands, compared to its average volume of 836,130. The company has a debt-to-equity ratio of 1.29, a current ratio of 2.90 and a quick ratio of 2.32. The company has a 50 day moving average price of $35.48 and a 200-day moving average price of $36.75. The firm has a market capitalization of $2.04 billion, a PE ratio of -16.06 and a beta of 1.32. Tandem Diabetes Care has a 1-year low of $24.42 and a 1-year high of $53.69.

Institutional Investors Weigh In On Tandem Diabetes Care

Several institutional investors have recently made changes to their positions in TNDM. Brooklyn Investment Group bought a new position in shares of Tandem Diabetes Care in the third quarter valued at approximately $28,000. Assetmark Inc. bought a new stake in Tandem Diabetes Care during the third quarter valued at $29,000. AlphaQuest LLC grew its position in Tandem Diabetes Care by 138.7% during the fourth quarter. AlphaQuest LLC now owns 931 shares of the medical device company's stock worth $34,000 after buying an additional 541 shares in the last quarter. Jones Financial Companies Lllp increased its stake in Tandem Diabetes Care by 195.8% in the 4th quarter. Jones Financial Companies Lllp now owns 1,130 shares of the medical device company's stock worth $41,000 after acquiring an additional 748 shares during the last quarter. Finally, Waldron Private Wealth LLC purchased a new position in shares of Tandem Diabetes Care during the third quarter worth about $50,000.

Tandem Diabetes Care Company Profile

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.